FDA
-
-
-
-
-
-
-
UK regulator accepts taletrectinib application for lung cancer review
-
-
-
-
-
-
-
Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Nuvation Bio Inc (NUVB)
-
-
-
-
-
-
-
B.Riley Reiterates Buy Rating on Nuvation Bio Inc (NUVB)
-
-
-
-
-
-
-
Truist Securities Starts Nuvation Bio Inc (NUVB) at Buy
-
-
-
-
-
-
-
Jefferies Starts Nuvation Bio Inc (NUVB) at Buy
-
-
-
-
-
-
-
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Ca
-
330,652 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

